Comparative safety of nivolumab plus ipilimumab versus nivolumab plus relatlimab in advanced melanoma: a pharmacovigilance study based on the FDA adverse event reporting system (FAERS)

Comparative safety of nivolumab plus ipilimumab versus nivolumab plus relatlimab in advanced melanoma: a pharmacovigilance study based on the FDA adverse event reporting system (FAERS)

Abstract Background Nivolumab combined with ipilimumab (NIVO-IPI) and nivolumab combined with relatlimab (NIVO-RELA) are approved treatments for advanced melanoma. However, the data on the differential adverse event (AE) risks associated with these two regimens are lacking. Methods We performed a di...

Full description

Saved in:
Bibliographic Details
Main Authors: Shanshan Xu, Zhihui Song, Dong Wang, Ente Wang, Jiawei Wang
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Cancer
Subjects:
Immune checkpoint inhibitor
Combination therapy
Heterogeneity
FAERS database
Disproportionality analysis
Advanced melanoma
Online Access:https://doi.org/10.1186/s12885-025-14546-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-14546-6

Similar Items